- A previous Collaborative Antiviral Study group found only 54% of infants
have no cutaneous recurrences in the six months after resolution of
cutaneous disease if untreated with suppressive therap.2
- A 2006 case study reports the development of HSV encephalitis in a
3-month-old female on oral acyclovir suppressive therapy. The study
warns against masking CNS disease with suppressive therapy.3
- Phase III clinical trials examining the use of oral acyclovir suppressive
therapy in infants with cutaneous and CNS disease have been ongoing
D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive
therapy after neonatal herpes simplex virus disease limited to the skin,
eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis
J. 1996; 15:247-54.
RJ, Arvin A, Prober C, et al. A controlled trial comparing vidarabine
with acyclovir in neonatal herpes simplex virus infection. N Eng
J Med. 1991;324:444-9.
M. Messina AF, Jafri HS, Sanchez PJ. Herpes simplex virus encephalitis
during suppressive therapy with acyclovir in a premature infant. Pediatrics.